Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023

選択的セロトニン再取り込み阻害薬(SSRI)の世界市場2019-2023

◆タイトル:Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023
◆商品コード:IRTNTR31583
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年7月20日
◆ページ数:127
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、選択的セロトニン再取り込み阻害薬(SSRI)の世界市場について調べ、選択的セロトニン再取り込み阻害薬(SSRI)の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、選択的セロトニン再取り込み阻害薬(SSRI)の市場規模をセグメンテーション別(用途別(うつ病、不安・パニック障害、その他の精神状態)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は選択的セロトニン再取り込み阻害薬(SSRI)の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・選択的セロトニン再取り込み阻害薬(SSRI)の市場状況
・選択的セロトニン再取り込み阻害薬(SSRI)の市場規模
・選択的セロトニン再取り込み阻害薬(SSRI)の市場予測
・選択的セロトニン再取り込み阻害薬(SSRI)の世界環境:ファイブフォース分析
・市場セグメンテーション:用途別(うつ病、不安・パニック障害、その他の精神状態)
・選択的セロトニン再取り込み阻害薬(SSRI)の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: About this market

Selective Serotonin Reuptake Inhibitors (SSRIs) are used to treat severe or persistent depression by elevating the extracellular levels of serotonin. Technavio’s selective serotonin reuptake inhibitors market analysis considers sales of the drugs for depression, anxiety and panic disorder, and other mental conditions. Our analysis also considers the sales of selective serotonin reuptake inhibitors in Asia, Europe, North America, and ROW. In 2018, the depression segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the rising incidence of depression, easy absorption of the drugs through the gastrointestinal tracts, and their selective activity toward 5-HT receptors will significantly help the depression segment in maintaining its leading market position. Also, our global selective serotonin reuptake inhibitors report has observed market growth factors such as the increased drug dependency associated with SSRIs, rising prevalence of mental illnesses, and favorable drug purchasing policies for patients. However, challenges such as side effects of antidepressants, advent of biologics, and stringent US FDA regulations and approval of psychotropic drugs may hamper the growth of the selective serotonin reuptake inhibitors industry over the forecast period.

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Overview

Rising prevalence of mental illnesses

The rising prevalence of mental illnesses, especially in the US, has been increasing the sales of neurological drugs such as SSRIs. These drugs have proven efficacy in treating depression. SSRIs are more effective compared with other available antidepressants. The growth potential of the market will attract new entrants. Therefore, the market is expected to record a CAGR of almost 4% during the forecast period.

Growing geriatric population

Mental disorders are common among older adults. The primary reason being most of the geriatric population have two or more chronic health conditions such as cardiovascular disease, hypertension, diabetes, and cancer, which are high-risk factors for mental disorders. The prevalence rate of mental conditions among the geriatric population is rising. Favorable health insurance policies are allowing people of this age group to avail treatment for mental disorders. This is creating market opportunities for vendors. Therefore, the growing geriatric population will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global selective serotonin reuptake inhibitors (SSRIs) market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global selective serotonin reuptake inhibitors market is fragmented. Technavio’s robust vendor analysis is designed to help clients in improving their market position, and in line with this, this report provides a detailed analysis of several leading selective serotonin reuptake inhibitors producers, which include Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, and Pfizer Inc.

Also, the selective serotonin reuptake inhibitors market analysis report includes information on upcoming trends and challenges that will influence the market growth. This is to help companies in strategizing and leveraging on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

Depression – Market size and forecast 2018-2023

Anxiety and panic disorder – Market size and forecast 2018-2023

Other mental conditions – Market size and forecast 2018-2023

Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Market positioning of vendors

Vendors covered

Vendor classification

Allergan Plc

Eli Lilly and Co.

GlaxoSmithKline Plc

H. Lundbeck AS

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Application – Market share 2018-2023 (%)

Exhibit 18: Comparison by application

Exhibit 19: Depression – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Depression – Year-over-year growth 2019-2023 (%)

Exhibit 21: Anxiety and panic disorder – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Prevalence of any anxiety disorder among US adults (2001-2003)

Exhibit 23: Past year severity of any anxiety disorder among US adults (2001-2003)

Exhibit 24: Anxiety and panic disorder – Year-over-year growth 2019-2023 (%)

Exhibit 25: Other mental conditions – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Prevalence of OCD among US adults (2001-2003)

Exhibit 27: Past year severity of OCD among US adults (2001-2003)

Exhibit 28: Other mental conditions – Year-over-year growth 2019-2023 (%)

Exhibit 29: Market opportunity by application

Exhibit 30: Customer landscape

Exhibit 31: Market share by geography 2018-2023 (%)

Exhibit 32: Geographic comparison

Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: North America – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in North America

Exhibit 36: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Europe

Exhibit 39: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in Asia

Exhibit 42: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 43: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 44: Top 3 countries in ROW

Exhibit 45: Key leading countries

Exhibit 46: Market opportunity

Exhibit 47: Prevalence scenario of AMI in US in 2017

Exhibit 48: Prevalence scenario of SMI in US in 2017

Exhibit 49: SSRI exposure 91 days either side of LMP and prevalence of congenital abnormality (CA) in three countries

Exhibit 50: Impact of drivers and challenges

Exhibit 51: Geriatric population scenario in US in 2017

Exhibit 52: CDC statistics about mental disorder in geriatric population in US over past few decades

Exhibit 53: Vendor landscape

Exhibit 54: Landscape disruption

Exhibit 55: Market positioning of vendors

Exhibit 56: Vendors covered

Exhibit 57: Vendor classification

Exhibit 58: Allergan Plc – Vendor overview

Exhibit 59: Allergan Plc – Business segments

Exhibit 60: Allergan Plc – Organizational developments

Exhibit 61: Allergan Plc – Geographic focus

Exhibit 62: Allergan Plc – Segment focus

Exhibit 63: Allergan Plc – Key offerings

Exhibit 64: Allergan Plc – Key customers

Exhibit 65: Eli Lilly and Co. – Vendor overview

Exhibit 66: Eli Lilly and Co. – Business segments

Exhibit 67: Eli Lilly and Co. – Organizational developments

Exhibit 68: Eli Lilly and Co. – Geographic focus

Exhibit 69: Eli Lilly and Co. – Segment focus

Exhibit 70: Eli Lilly and Co. – Key offerings

Exhibit 71: Eli Lilly and Co. – Key customers

Exhibit 72: GlaxoSmithKline Plc – Vendor overview

Exhibit 73: GlaxoSmithKline Plc – Business segments

Exhibit 74: GlaxoSmithKline Plc – Organizational developments

Exhibit 75: GlaxoSmithKline Plc – Geographic focus

Exhibit 76: GlaxoSmithKline Plc – Segment focus

Exhibit 77: GlaxoSmithKline Plc – Key offerings

Exhibit 78: GlaxoSmithKline Plc – Key customers

Exhibit 79: H. Lundbeck AS – Vendor overview

Exhibit 80: H. Lundbeck AS – Business segments

Exhibit 81: H. Lundbeck AS – Organizational developments

Exhibit 82: H. Lundbeck AS – Geographic focus

Exhibit 83: H. Lundbeck AS – Key offerings

Exhibit 84: H. Lundbeck AS – Key customers

Exhibit 85: Pfizer Inc. – Vendor overview

Exhibit 86: Pfizer Inc. – Business segments

Exhibit 87: Pfizer Inc. – Organizational developments

Exhibit 88: Pfizer Inc. – Geographic focus

Exhibit 89: Pfizer Inc. – Segment focus

Exhibit 90: Pfizer Inc. – Key offerings

Exhibit 91: Pfizer Inc. – Key customers

Exhibit 92: Validation techniques employed for market sizing

Exhibit 93: Definition of market positioning of vendors



【掲載企業】

Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, and Pfizer Inc.

★調査レポート[選択的セロトニン再取り込み阻害薬(SSRI)の世界市場2019-2023] (Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023 / IRTNTR31583)販売に関する免責事項
[選択的セロトニン再取り込み阻害薬(SSRI)の世界市場2019-2023] (Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023 / IRTNTR31583)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆